- Home
- ALVO
ALVO
Alvotech
as 07-26-2024 4:00pm EST
Alvotech is an integrated biopharmaceutical company committed to developing and manufacturing high-quality biosimilar medicines for patients globally. its purpose is to improve the health and quality of life of patients around the world by improving access to proven treatments for various diseases.
| Founded: | 2013 | Country: | Iceland |
| Employees: | N/A | City: | N/A |
| Market Cap: | 3.9B | IPO Year: | N/A |
| Target Price: | $16.00 | AVG Volume (30 days): | 72.2K |
| Analyst Decision: | Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.08 | EPS Growth: | N/A |
| 52 Week Low/High: | $8.29 - $18.00 | Next Earning Date: | 08-28-2024 |
| Revenue: | $114,393,000 | Revenue Growth: | 14.27% |
| Revenue Growth (this year): | 352.21% | Revenue Growth (next year): | 51.33% |
Latest Alvotech News
ALVO Breaking Stock News: Dive into ALVO Ticker-Specific Updates for Smart Investing
GlobeNewswire
5 days ago
STADA and Alvotech launch Uzpruvo, the first approved ustekinumab biosimilar to Stelara, across Europe
GlobeNewswire
16 days ago
Alvotech Announces Closing of Private Debt Financing
GlobeNewswire
16 days ago
Alvotech Announces Closing of Private Debt Financing
GlobeNewswire
24 days ago
Alvotech Announces Positive Topline Results from Confirmatory Patient Study for AVT03, a Proposed Biosimilar for Prolia® and Xgeva®
GlobeNewswire
25 days ago
Alvotech Issues New Shares to Holders of Convertible Bonds
GlobeNewswire
a month ago
Alvotech Announces Record Preliminary Results for Revenues and EBITDA for the Second Quarter of 2024
GlobeNewswire
a month ago
Alvotech Receives Conversion Notices for Majority of Convertible Bonds
GlobeNewswire
a month ago
Alvotech Receives Conversion Notices for Majority of Convertible Bonds
Compare ALVO vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ALVO Alvotech - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.